taf real world study for universal effectiveness

Conditions: Chronic Hepatitis b

Summary: this study is a multi-center, prospective, real-world study, males and non-pregnant, non-lactating female hbeag positive or negative patients (above 18 years of age) who were mono-infected with hbv, either na treatment-naïve or treatment-experienced, but taf naïve will be enrolled in this study, and they will be treated with taf, alone or in combination with other hbv antivirals. during 36 months of treatment, efficacy and safety will be evaluated.

this study is a multi-center, prospective, real-world study, aiming to investigate the use of taf in routine clinical management of chronic hepatitis b patients and evaluate its effectiveness and safety across a heterogeneous population in china. approximately 500 patients will take part in this study, 10 sites will be included which distribute in china's major cities, thus each site will enroll 50 patients. male or female hbeag positive or negative patients (above 18 years of age) who were mono-infected with hbv, either na treatment-naïve or treatment-experienced, but taf naïve will be enrolled in this study, and they will be treated with taf, alone or in combination with other hbv antivirals. during 36 months of treatment, efficacy and safety will be evaluated.

Eligibility criteria:
inclusion criteria: 1. must have the ability to understand and sign a written informed consent form, consent must be obtained prior to initiation of study procedures 2. adult males and nonpregnant, nonlactating females 3. documented evidence of chronic hbv infection previously 4. taf naive exclusion criteria: 1. patents who were taf experienced 2. women who are breastfeeding 3. pregnant females 4. co-infection with hepatitis a virus (hav), hepatitis c virus (hcv), hepatitis d virus (hdv), or hiv 5. evidence of hepatocellular carcinoma (note: if screening alpha-fetoprotein (afp) is \ 50 ng/ml an imaging study is required) 6. chronic liver disease of non-hbv etiology (e.g., hemochromatosis, fatty liver disease, cholangitis) 7. current evidence of child-pugh score c decompensated liver disease,or moderate to severe ascites, grade iii-iv hepatic encephalopathy 8. abnormal hematological and biochemical parameters, including: 9. albumin \< 2.8 mg/ dl 10. international normalized ratio (inr) \> 2.3 x uln (unless stable on anticoagulant regimen) 11. total bilirubin \> 3 x uln 12. patient develops clinical or laboratory findings suggestive of lactic acidosis or pronounced hepatotoxicity 13. received solid organ or bone marrow transplant, except patients who underwent liver or kidney transplantation 14. malignancy within 5 years prior to screening, with the exception of specific cancers that are cured by surgical resection (e.g., basal cell skin cancer). individuals under evaluation for possible malignancy are not eligible. 15. individuals receiving ongoing therapy with drugs not to be used with taf or individuals with a known hypersensitivity to study drugs, metabolites, or formulation excipients 16. any other clinical condition or prior therapy that, in the opinion of the investigator, would make the individual unsuitable for the study or unable to comply with dosing requirements 17. use of investigational agents within 3 months of screening, unless allowed by the sponsor 18. patients included in another trial or having been given investigational drugs within 12 weeks prior to screening 19. current alcohol or substance abuse judged by the investigator to potentially interfere with compliance 20. inability or unwillingness to provide informed consent or abide by the requirements of the study 21. in addition to the above exclusion criteria, patients who meet any of the contraindications for taf